AnaptysBio Inc.

Faga sold roughly $63K in ANAB stock — a modest amount for a CEO, likely reflecting routine liquidity or programmatic disposition rather than a directional signal. At just over 1,000 shares, this is too small to read as a meaningful change in conviction. Worth monitoring for pattern escalation but not actionable on its own.

Faga sold ~$198K in ANAB stock, a relatively modest disposal for a CEO-level position. At ~$65/share, this is well off ANAB's historical highs, and the size suggests routine liquidity or tax planning rather than a bearish signal—worth monitoring whether this is part of a 10b5-1 plan. No red flag on its own, but would become notable if followed by additional insider selling ahead of clinical readouts.

Daniel Faga sold 510 shares of ANAB for ~$28.9K, a negligible amount that likely reflects routine tax withholding or planned disposition rather than any directional signal. At just $28K, this is not a meaningful liquidity event for a CEO of a mid-cap biotech. No actionable read here absent a pattern of larger or accelerating sales.

Faga sold a modest 2,570 shares at ~$57.91, a relatively small disposition for a CEO that likely reflects routine liquidity or tax-related planning rather than a directional signal. ANAB has had significant volatility tied to its immunology pipeline (rosnilimab, imsidolimab), so the size and timing should be weighed against any upcoming data readouts. This alone wouldn't warrant a bearish read, but worth monitoring if additional insiders begin selling or if the pace accelerates.

Faga sold ~$215K in ANAB shares, a modest disposal for a CEO-level position. Without additional context—such as 10b5-1 plan participation, tax obligations, or upcoming option expirations—this is low-signal; routine liquidity sales by CEOs are common and this represents a small fraction of typical executive holdings. Worth monitoring for clustered insider selling or acceleration in pace, but standalone this doesn't warrant a directional read.

Faga sold a modest 550 shares (~$33K) of ANAB at ~$60.63, a relatively small transaction for a CEO that likely reflects routine liquidity or tax-related planning rather than a directional signal. AnaptysBio's pipeline-stage valuation makes insider sales worth monitoring, but the size here is too small to indicate meaningful conviction against the stock. Would need to see clustering of insider sales or significantly larger volumes to flag this as actionable.

Faga sold a modest 2,592 shares (~$164K) at $63.35, a relatively small disposition for a CEO-level position. Without knowing his remaining holdings, this could easily represent routine liquidity, tax planning, or 10b5-1 plan execution rather than a directional signal. Worth monitoring for follow-on sales or whether this is an isolated event, but the size alone doesn't flag meaningful concern.

Faga sold ~$203K in ANAB shares, a relatively modest disposal for a CEO-level position. Without additional context—such as 10b5-1 plan scheduling, options expiration, or personal liquidity needs—a single small sale from a biotech CEO is low-signal; it warrants monitoring but not alarm. Worth watching whether additional insider sales follow or if this remains isolated ahead of any upcoming clinical readouts.

**Insider Transaction Note — ANAB** CEO Daniel Faga sold just 100 shares (~$6,600 total), a negligible amount that almost certainly represents a tax withholding event or administrative transaction rather than a directional signal. At this size, this sale carries essentially zero informational value regarding management's outlook on AnaptysBio's pipeline or stock trajectory. Disregard as noise.